This retrospective study investigated factors influencing the steady-state trough
concentrations (C trough) of rivaroxaban in patients with nonvalvular atrial fibrillation …

Background Routine laboratory monitoring of rivaroxaban and dose adjustment relating to
exposure is currently not recommended. However, in certain clinical situations, assessment …

Rivaroxaban exposure and patient characteristics may affect the rivaroxaban benefit–risk
balance. This study aimed to quantify associations between model-predicted rivaroxaban …

In Japanese surveillance in an early phase after the approval of rivaroxaban, inappropriate
underdose was frequently utilized. The aim of this study was to describe the prevalence and …

Background Rivaroxaban is a direct oral anticoagulant (DOAC) approved for the treatment of
non-valvular atrial fibrillation (NVAF). Data related to the risk factors associated with …

Background: Prothrombin time (PT) distribution in Japanese nonvalvular atrial fibrillation
(NVAF) patients under rivaroxaban therapy remains to be clarified. Methods and Results …

Background In nonvalvular atrial fibrillation (NVAF), rivaroxaban is used to prevent stroke
and systemic embolism. Objective To evaluate major bleeding (MB) in NVAF patients treated …

Aims Limited real-world data show that rivaroxaban following dosage criteria from either
ROCKET AF [20 mg/day or 15 mg/day if creatinine clearance (CrCl)< 50 mL/min] or J …

Low-dose rivaroxaban has been used in Asian patients with direct oral anticoagulants
(DOACs) eligible for atrial fibrillation (AF). However, there are few pharmacokinetic (PK) data …

The approved dose of oral anticoagulant rivaroxaban for patients with non-valvular atrial
fibrillation (NVAF) in Japan is 15 mg once daily (od) in patients whose creatinine clearance …